Ascidian Therapeutics, Inc
Clinical trials sponsored by Ascidian Therapeutics, Inc, explained in plain language.
-
Gene therapy injection aims to slow vision loss in stargardt disease
Disease control Recruiting nowThis early-stage study tests a single injection of ACDN-01 into the eye for people with Stargardt disease or cone-rod dystrophy caused by ABCA4 gene mutations. The main goals are to check safety and find the best dose. About 15 adults with advanced vision loss will take part. The…
Phase: PHASE1, PHASE2 • Sponsor: Ascidian Therapeutics, Inc • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Eye screening study opens door to future treatments
Knowledge-focused Recruiting nowThis study is a pre-screening step for people with Stargardt disease or cone-rod dystrophy caused by ABCA4 gene mutations. It uses genetic tests and eye exams to see who may qualify for upcoming ACDN-01 clinical trials. About 50 participants will be enrolled to confirm their diag…
Sponsor: Ascidian Therapeutics, Inc • Aim: Knowledge-focused
Last updated May 15, 2026 11:56 UTC